Study shows patients with acute heart failure assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo.
A new study led by Dr. Paul Chan shows Black and Hispanic individuals who experience cardiac arrest at home or in public are less likely to receive CPR from a bystander than white individuals.